9 Meters Biopharma Inc (FRA:2Q3A)

€ 0.0123 -0.0082 (-40%) Market Cap: 210,000.00 Enterprise Value: -1.40 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 0/100

9 Meters Biopharma Inc at William Blair Biotech Focus Conference Transcript
Jul 12, 2022
9 Meters Biopharma Inc at BMO Biopharma Spotlight Series: Innovation in GI (Virtual) Transcript
Aug 12, 2021
9 Meters Biopharma Inc Host KOL Perspectives on Short Bowel Syndrome & NM-002 Program Update Corporate Call Transcript
Mar 23, 2021
9 Meters Biopharma, Inc. - Special Call Transcript
Aug 18, 2020
Innovate Biopharmaceuticals Inc R&D Day (Virtual) Transcript
May 13, 2020
Innovate Biopharmaceuticals, Inc., RDD Pharma, Ltd. - M&A Call Transcript
May 04, 2020
Innovate Biopharmaceuticals Inc Analyst Event to Discuss NASH Data and Provide Clinical Updates Transcript
May 20, 2019
Q1 2019 Innovate Biopharmaceuticals Inc Earnings Call Transcript
Apr 29, 2019

€33.4 (-7.18%)

Earnings
Q4 2018 Innovate Biopharmaceuticals Inc Earnings Call Transcript
Mar 18, 2019

Earnings

Innovate Biopharmaceuticals Inc R&D Day (Virtual) Transcript

May 13, 2020 / 05:00PM GMT

Release Date Price: €13

Transcript 10-Q

Operator

Good day, and welcome to the 9 Meters Biopharma R&D Day Webinar on clinical pipeline advancement of gastrointestinal therapies in short bowel syndrome and celiac disease. (Operator Instructions) Please note, this conference is being recorded.

I will now turn the call over to John Temperato, President and CEO of 9 Meters Biopharma. Please go ahead, sir.

John Temperato

9 Meters Biopharma, Inc. - President, CEO & Director

Thank you, and hello, everyone, and good afternoon, and welcome to the 9 Meters Biopharma R&D Day, where we will focus on our 2 lead assets, and as such, we are very fortunate to have 2 world-class key opinion leaders with us today. Dr. Mark Pimentel will provide an overview of our long-acting GLP-1 agonist for short bowel syndrome, while Dr. Benjamin Lebwohl will provide an update on larazotide, our tight-junction regulator, for celiac disease. However, since we just started trading under the 9 Meters to MAST Head after the transformational mergers between Innovate Biopharmaceuticals, RDD Pharma and Naia Rare Diseases, I'd

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.